Oral GS-5806 activity in a respiratory syncytial virus challenge study

Area of Science:

• Virology
• Infectious Diseases
• Pharmacology

Background:

• Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations and mortality.
• Currently, no universally accepted antiviral treatment exists for RSV infections.

Purpose of the Study:

• To evaluate the efficacy and safety of GS-5806, an oral RSV-entry inhibitor, in a human challenge study.
• To assess the impact of GS-5806 on viral load, mucus weight, and symptom scores.

Main Methods:

• A double-blind, placebo-controlled study was conducted in healthy adults inoculated with RSV.
• Participants received varying doses of GS-5806 or placebo after RSV infection confirmation.
• Viral load, mucus weight, and symptom scores were primary and secondary endpoints.

Main Results:

• GS-5806 treatment significantly reduced RSV viral load (P<0.001) and mucus weight (P=0.03).
• A significant reduction in symptom scores was observed in the GS-5806 group (P=0.005).
• Adverse events, including neutropenia and elevated ALT, were more frequent with GS-5806.

Conclusions:

• GS-5806 effectively reduced viral load and clinical disease severity in a healthy adult RSV challenge model.
• The findings suggest GS-5806 is a potential therapeutic agent for RSV.
• Further investigation is warranted, considering the observed adverse events.